{"id":521151,"date":"2021-08-02T08:03:43","date_gmt":"2021-08-02T12:03:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/"},"modified":"2021-08-02T08:03:43","modified_gmt":"2021-08-02T12:03:43","slug":"avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/","title":{"rendered":"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DUBLIN, Ireland, Aug.  02, 2021  (GLOBE NEWSWIRE) &#8212; Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 9, 2021, to provide a corporate update and discuss the Company&#8217;s financial results for the second quarter ended June 30, 2021.<\/p>\n<p>To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 4560878. A live audio webcast can be accessed by visiting the investor relations section of the Company\u2019s website, www.avadel.com. A replay of the webcast will be archived on Avadel\u2019s website for 90 days following the event.<\/p>\n<p>\n        <strong>About Avadel Pharmaceuticals plc<\/strong><br \/>\n        <br \/>Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and U.S. Food and Drug Administration (FDA) approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gt5iGq50_887uNwGSjjqYOHhPHkoUmTgzcLzRiWpGf7Ht4wF9GbNlVXxZ4hN-tz3DJICogiA-s-5bep_X2UFYw==\" rel=\"nofollow noopener\" target=\"_blank\">www.avadel.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Courtney Turiano<br \/>Stern Investor Relations, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MX_ztHae6C-qPremC_eRr5aNFQiywpMiriz5OlvvFQ6sD8fJG2WXLhPaoAAhfEtxGL9YAouVQRaYIOSv7O9RmUYL3Obl3XooojiAiBGmehj_qax3IhuErO2kXM9M2sGf\" rel=\"nofollow noopener\" target=\"_blank\">Courtney.Turiano@sternir.com<\/a><br \/>(212) 698-8687<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Nicole Raisch Goelz<br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MAZOh1NRW8SL4TDQ5T3yXlChWl_VvQ4LH5mi54oBKn-O-ky-nECwkR6GJJaP7KGPfC1uOZa2DOfn5sCMBlZWNW90Q9GEDX3l_wKwpuS6328=\" rel=\"nofollow noopener\" target=\"_blank\">ngoelz@realchemistry.com<\/a><br \/>(408) 568-4292<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/05924181-9210-4217-b7db-c8d9a6426141\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 9, 2021, to provide a corporate update and discuss the Company&#8217;s financial results for the second quarter ended June 30, 2021. To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 4560878. A live audio webcast can be accessed by visiting the investor relations section of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521151","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 9, 2021, to provide a corporate update and discuss the Company&#8217;s financial results for the second quarter ended June 30, 2021. To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 4560878. A live audio webcast can be accessed by visiting the investor relations section of the &hellip; Continue reading &quot;Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T12:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th\",\"datePublished\":\"2021-08-02T12:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/\"},\"wordCount\":230,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/\",\"name\":\"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=\",\"datePublished\":\"2021-08-02T12:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/","og_locale":"en_US","og_type":"article","og_title":"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th - Market Newsdesk","og_description":"DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 9, 2021, to provide a corporate update and discuss the Company&#8217;s financial results for the second quarter ended June 30, 2021. To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 4560878. A live audio webcast can be accessed by visiting the investor relations section of the &hellip; Continue reading \"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T12:03:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th","datePublished":"2021-08-02T12:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/"},"wordCount":230,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/","name":"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=","datePublished":"2021-08-02T12:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDMxMSM0MzI0NDMxIzIwOTA5NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financial-results-on-august-9th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521151"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521151\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}